TradeUP Acquisition Corp

TradeUP Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 6, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. ("UPTD") (NASDAQ: UPTD, UPTDW, UPTDU), today announced the successful closing of its business combination with Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China's UP Fintech. The cancer therapy developer was only founded last year but thinks it can start generating revenue as soon as 2025 using proprietary technology from its founder. Its lack of revenue and unclear future prospects, combined with uncertainties related to its China ties, mean its stock could quickly come under pressure if and when it finally completes its SPAC listing.

Estrella Immunopharma Nears Completion Of SPAC Listing

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from September 19, 2023 to October 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company.

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

TradeUP Acquisition (NASDAQ: UPTD ) stock is falling on Tuesday as the company's shares give up gains seen during a recent rally. Investors following UPTD stock will note that its shares climbed a massive 201.4% during normal trading hours on Friday.

Why Is TradeUP Acquisition (UPTD) Stock Down 33% Today?

TradeUP Acquisition (NASDAQ: UPTD ) stock is gaining on Tuesday after the company provided investors with an update on its business. TradeUP Acquisition is a SPAC currently seeking to combine with pharmaceutical company Estrella Biopharma.

Why Is TradeUP Acquisition (UPTD) Stock Up 40% Today?

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. ("TradeUP") (NASDAQ: UPTD), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement on September 30, 2022 that will result in Estrella becoming a publicly listed company.

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

News for TradeUP Acquisition Corp Stock (UPTD)